Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
239actual
Sites
143
Countries
Australia, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-20 | actual | When the study began enrolling |
| Primary completion | 2026-01-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-cell Lymphoma
Interventions
- Drug: Brentuximab vedotin
- Drug: Rituximab
- Drug: Lenalidomide
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS)
measured Approximately 2 years
Publications
- PMID 39772655 — linked by the registry
- PMID 34780623 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed